+ Transgender and the Feminist Perspective By: Alexandra Berard.
Canadian Diabetes Association Clinical Practice Guidelines Monitoring for Glycemic Control Chapter 9...
-
Upload
chester-gallagher -
Category
Documents
-
view
213 -
download
0
Transcript of Canadian Diabetes Association Clinical Practice Guidelines Monitoring for Glycemic Control Chapter 9...
Canadian Diabetes Association Clinical Practice Guidelines
Monitoring for Glycemic Control
Chapter 9
Lori Berard, Ian Blumer, Robyn Houlden, David Miller, Vincent Woo
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Key Messages
1. Glycated hemoglobin (A1C) measure every 3
months (6 months if stable at target)
2. Self monitoring Blood Glucose (SMBG) is an aid to
assess interventions and hypoglycemia
3. Individualize the frequency of SMBG
4. SMBG and continuous glucose monitoring (CGM)
needs to be linked with structured educational
program to facilitate behaviour change
2013
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Glycated Hemoglobin: A1C
• Reliable measure of mean plasma glucose over 3-4 months
• Valuable indicator of treatment effectiveness
• Measure every 3 months when glycemic targets are not being met or treatments adjusted
• Measure every 6 months if stable at glycemic targets
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Recognize pitfalls of A1C: Conditions that can Affect Value
Factors affecting A1C
Increased A1C Decreased A1C Variable Change in A1C
Erythropoiesis B12/Fe deficiency Decreased erythropoiesis
Use of EPO, Fe, or B12Reticulocytosis Chronic liver Dx
Altered hemoglobin
Fetal hemoglobin Hemoglobinopathies Methemoglobin
Altered glycation Chronic renal failure ↓↓erythrocyte pH
ASA, vitamin C/E Hemoglobinopathies ↑ erythrocyte pH
Erythrocyte destruction
Splenectomy HemoglobinopathiesChronic renal failureSplenomegalyRheumatoid arthritisHAART meds, RibavirinDapsone
Assays HyperbilirubinemiaCarbamylated HbETOHChronic opiates
Hypertriglyceridemia
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
A1C Reporting: NGSP vs. IFCC Units
• Canada continues to report A1C in NGSP units of %
• Some countries report A1C in IFCC SI units (mmol/mol) instead of the NGSP units
• The equation below can be used to convert A1C from NGSP (%) to IFCC (mmol/mol)
IFCC (mmol/mol) = 10.93(NGSP%) – 23.50
NGSP (%) IFCC (mmol/mol)
4.0 20
5.0 31
6.0 42
6.5 48
7.0 53
8.0 64
9.0 75
10.0 86
11.0 97
12.0 108
NGSP = National Glycohemoglobin Standardization Program; IFCC = International Federation of Clinical Chemistry and Laboratory Medicine
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
SMBG is a tool, not an intervention
Teach patients to
“MONITOR WITH MEANING”
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Monitoring with Meaning …
• SMBG accompanied by structured educational
program to facilitate behaviour change results in
improved outcomes
• Teach patients
1. How and when to perform SMBG
2. How to record the results
3. Meaning of various BG levels
4. How behaviour and actions affect SMBG results
1. Parkin CG et al. J Diabetes Sci Technol. 2009;3:500-508. 2. Polonsky WH, et al. Diabetes Care. 2011;34:262-267.
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Individualize Frequency of SMBG
• CDA SMBG tool - provides guidance on appropriate
situations for SMBG utilization
http://guidelines.diabetes.ca
2013
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Regular SMBG is required:
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Increased frequency of SMBG may be required:
Daily SMBG is not usually required if:
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Recommendation 1
1. For most individuals with diabetes, A1C should be
measured every 3 months to ensure that glycemic
goals are being met or maintained.
Testing at least every 6 months should be
performed in adults during periods of treatment
and lifestyle stability when glycemic targets
have been consistently achieved [Grade D,
Consensus].
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Recommendation 2
2. For individuals using insulin more than once a day,
SMBG should be used as an essential part of
diabetes self-management [Grade A, Level 1, for type 1 diabetes;
Grade C, Level 3 for type 2 diabetes] and should be undertaken
at least 3 times per day [Grade C, Level 3] and include
both pre- and postprandial measurements [Grade C,
Level 3].
In those with type 2 diabetes on once-daily
insulin in addition to oral antihyperglycemic
agents, testing at least once a day at variable
times is recommended [Grade D, Consensus].
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
When glycemic control is not being achieved, SMBG should include both pre-and postprandial measurements to modify lifestyle and medications [Grade A, Level 1].
If achieving glycemic targets or receiving medications not associated with hypoglycemia, infrequent SMBG is appropriate [Grade D, Consensus].
Recommendation 3
3. For individuals with type 2 diabetes not receiving insulin therapy, SMBG recommendations should be individualized depending on type of antihyperglycemic agents, level of glycemic control, and risk of hypoglycemia. [Grade D, Consensus].
2013
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Recommendation 4
4. In many situations, for all individuals with diabetes,
more frequent testing should be undertaken to
provide information needed to make behavioural or
treatment adjustments required to achieve desired
glycemic targets and avoid risk of hypoglycemia [Grade D, Consensus].
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Recommendation 5
5. In people with type 1 diabetes with inadequate
glycemic control despite an optimal treatment
regimen, real-time continuous glucose
monitoring may be used to improve glycemic
control [Grade B, Level 2] and reduce hypoglycemia [Grade B,
Level 2].
2013
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Recommendation 6
6. In order to ensure accuracy of BG meter readings,
meter results should be compared with laboratory
measurement of simultaneous venous FPG at
least annually, and when indicators of glycemic
control do not match meter readings [Grade D, Consensus].
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
Recommendation 7
7. Individuals with type 1 diabetes should be
instructed to perform ketone testing during periods
of acute illness accompanied by elevated BG,
when preprandial BG levels remain >14.0 mmol/L or
in the presence of symptoms of DKA [Grade D, Consensus].
Blood ketone testing methods may be preferred
over urine ketone testing, as they have been
associated with earlier detection of ketosis and
response to treatment [Grade B, Level 2].
guidelines.diabetes.ca | 1-800-BANTING (226-8464) | diabetes.caCopyright © 2013 Canadian Diabetes Association
CDA Clinical Practice Guidelines
http://guidelines.diabetes.ca – for professionals
1-800-BANTING (226-8464)
http://diabetes.ca – for patients